Your browser doesn't support javascript.
loading
The Brighton Collaboration standardized template for collection of key information for benefit-risk assessment of inactivated viral vaccines.
Kochhar, Sonali; Excler, Jean-Louis; Kim, Denny; Robertson, James S; Fast, Patricia E; Condit, Richard C; Drew, Stephen; Wood, David; Gurwith, Marc; Klug, Bettina; Whelan, Mike; Khuri-Bulos, Najwa; Mallett Moore, Tamala; Smith, Emily R; Chen, Robert T.
Afiliación
  • Kochhar S; Global Healthcare Consulting, New Delhi, India; University of Washington, Seattle, WA, USA.
  • Excler JL; International Vaccine Institute, Seoul, Republic of Korea.
  • Kim D; Janssen Pharmaceuticals, Titusville, NJ, USA.
  • Robertson JS; Independent Adviser, UK.
  • Fast PE; International AIDS Vaccine Initiative, New York, NY, USA; Stanford School of Medicine, Palo Alto, CA, USA.
  • Condit RC; Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, FL, USA.
  • Drew S; Independent Adviser, USA.
  • Wood D; Independent Adviser, UK.
  • Gurwith M; Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.
  • Klug B; Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany.
  • Whelan M; Project Leader, CEPI, UK.
  • Khuri-Bulos N; University of Jordan, Amman, Jordan.
  • Mallett Moore T; Sanofi Pasteur, Swiftwater, PA, USA.
  • Smith ER; Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.
  • Chen RT; Brighton Collaboration, A Program of the Task Force for Global Health, Decatur, GA, USA.
Vaccine ; 38(39): 6184-6189, 2020 09 03.
Article en En | MEDLINE | ID: mdl-32747214
Inactivated viral vaccines have long been used in humans for diseases of global health threat and are now among the vaccines for COVID-19 under development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of inactivated viral vaccines. This will help key stakeholders to assess potential safety issues and understand the benefit-risk of the vaccine platform. The standardized and structured assessment provided by the template would also help to contribute to improved communication and support public acceptance of licensed inactivated viral vaccines.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neumonía Viral / Vacunas Virales / Aprobación de Drogas / Infecciones por Coronavirus / Medición de Riesgo / Pandemias Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Vaccine Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neumonía Viral / Vacunas Virales / Aprobación de Drogas / Infecciones por Coronavirus / Medición de Riesgo / Pandemias Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Vaccine Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Países Bajos